Epicrispr Biotechnologies Secures $68 Million Series B to Initiate Clinical Trial for First-in-Class Disease-Modifying Epigenetic Neuromuscular Therapy for FSHD
– Financing led by Ally Bridge Group, with participation from SOLVE FSHD, a venture philanthropy organization – Lead program, EPI-321, is the first clinical application of epigenetic modulation in neuromuscular diseases, with a first-in-human trial…